公开(公告)号：EP2011518A1

公开(公告)日：2009-01-07

申请号：EP07741475.3

申请日：2007-04-12

申请人： Otsuka Pharmaceutical Co., Ltd.

发明人： INADA, Makoto ,  KUNIZAKI, Jun-ichi ,  IKEI, Nobuhiro ,  NATSUME, Kuniaki

IPC分类号： A61K49/00 ,  C07D239/46

CPC分类号： C07D239/46 ,  A61K49/0004 ,  G01N33/497 ,  Y10T436/204998

摘要： The present invention provides a composition for measuring the gastric-emptying function and a method for measuring the gastric-emptying function effectively usable in diagnosing dyspepsia. The present invention also provides a dyspepsia diagnostic agent, a method for diagnosing dyspepsia, and a method for measuring the treatment effect on a patient suffering from gastrointestinal disorders caused by insufficiencies in the gastric-emptying function (including a pharmacotherapy). One of the main features of the composition for measuring the gastric-emptying function of the present invention is that a pyrimidine compound, which is converted to a labeled CO 2 gas in the body and excreted in expired air, labeled with an isotope of C or O, is used as an active ingredient. The method of the present invention can be conducted by orally administering the composition to a subject, and measuring the amount or behavior of the labeled CO 2 excreted in expired air.

摘要翻译： 本发明提供了一种用于测量胃排空功能的组合物和用于测量有效可用于诊断消化不良的胃排空功能的方法。 本发明还提供消化不良诊断剂，诊断消化不良的方法，以及测定由胃排空功能不足引起的胃肠道疾病患者（包括药物治疗）的治疗效果的测定方法。 用于测量本发明的胃排空功能的组合物的主要特征之一是将嘧啶化合物转化为体内标记的CO 2气体并在呼出空气中排出，用C或C的同位素标记 O被用作活性成分。 本发明的方法可以通过向受试者口服施用该组合物，并测量在呼出空气中排出的标记的CO 2的量或行为。

公开(公告)号：EP1983047A1

公开(公告)日：2008-10-22

申请号：EP07708219.6

申请日：2007-02-08

申请人： Educational Foundation Jichi Medical University ,  OTSUKA PHARMACEUTICAL CO., LTD.

发明人： YOSHIDA, Shigeto ,  OHBA, Yoshio ,  HARIGUCHI, Norimitsu ,  MIZUKOSHI, Masami ,  KAWASAKI, Masanori ,  MATSUMOTO, Makoto ,  GOTO, Yoshihiro

IPC分类号： C12N15/00 ,  A61K35/76 ,  A61K39/12 ,  A61P31/12 ,  C12N7/00 ,  C12N15/09

CPC分类号： C12N15/86 ,  A61K39/00 ,  A61K39/015 ,  A61K39/04 ,  A61K39/12 ,  A61K39/145 ,  A61K2039/525 ,  A61K2039/5256 ,  A61K2039/543 ,  A61K2039/544 ,  C07K14/005 ,  C07K2319/02 ,  C07K2319/43 ,  C12N2710/14143 ,  C12N2760/16134 ,  C12N2830/205 ,  Y02A50/386 ,  Y02A50/394 ,  Y02A50/41 ,  Y02A50/412

摘要： A recombinant transfer vector capable of expressing a foreign gene fused to a viral gene under the control of dual promoters and a recombinant baculovirus, and methods for production thereof, as well as pharmaceuticals comprising the recombinant baculovirus as an active ingredient.

摘要翻译： 能够在双重启动子和重组杆状病毒的控制下表达与病毒基因融合的外源基因的重组转移载体及其制备方法，以及包含重组杆状病毒作为活性成分的药物。

公开(公告)号：EP1114861B8

公开(公告)日：2008-10-01

申请号：EP99943357.6

申请日：1999-09-16

申请人： Otsuka Pharmaceutical Co., Ltd.

发明人： HORIE, Masato ,  OKUTOMI, Keiichi c/o OTSUKA PHARMACEUTICAL CO.LTD. ,  TANIGUCHI, Yoshihiro ,  SUZUKI, Mikio c/o OTSUKA PHARMACEUTICAL CO.LTD. ,  OHBUCHI, Yutaka

IPC分类号： C12N15/12 ,  C12N15/63 ,  C12N5/10 ,  C07K14/705 ,  C07K16/28 ,  C12Q1/68 ,  A61K38/17 ,  A61K48/00 ,  G01N33/68

CPC分类号： C07K14/705 ,  A61K38/00 ,  A61K48/00

摘要： A brain-specific gene useful in treating Alzheimer's disease, etc. which contains a base sequence encoding the amino acid sequence represented by SEQ ID NO:1; a fragment thereof; an expression vector containing the gene; a host cell containing the expression vector; an expression product of the gene; an antibody against the same; and remedies and preventives for nerve degeneration diseases, etc.

公开(公告)号：EP1291429B1

公开(公告)日：2008-09-03

申请号：EP01938602.8

申请日：2001-06-12

申请人： OTSUKA PHARMACEUTICAL CO., LTD.

发明人： FUJIWARA, Tsutomu ,  OKAMOTO, Takashi ,  NIIMI, Masashi ,  KYUSHIKI, Hiroyuki ,  YAMAMOTO, Yasuchika ,  UEYAMA, Atsunori

IPC分类号： C12N15/53 ,  C12N9/10 ,  C12N9/12 ,  C12Q1/48

CPC分类号： C12N9/1096 ,  A61K48/00

摘要： The present invention is drawn to a gene comprising a polynucleotide encoding a polypeptide composed of an amino acid sequence represented by SEQ ID NO: 1; a gene expression product produced through expression of the gene; a recombinant expression vector including the gene; a host cell (transformant) harboring the recombinant expression vector; a protein composed of an amino acid having an amino acid sequence represented by SEQ ID NO: 1; a therapeutic or preventive composition for hypoglycemia containing as an active ingredient the above-mentioned gene or protein; and an antibody capable of binding to the protein. Through use of the gene or an expression product thereof of the present invention, it is possible to elucidate the pathology of diabetes and develop drugs for treatment and prevention of diabetes via a new action mechanism.

公开(公告)号：EP1957073A2

公开(公告)日：2008-08-20

申请号：EP06834365.6

申请日：2006-12-04

申请人： OTSUKA PHARMACEUTICAL CO., LTD.

发明人： MATSUYAMA, Hironori ,  OHNISHI, Kenji ,  NAKAGAWA, Takashi ,  TAKASU, Hideki ,  SAKAMOTO, Makoto ,  HIGUCHI, Kumi ,  MIYAJIMA, Keisuke ,  YAMADA, Satoshi ,  MOTOYAMA, Masaaki ,  KOJIMA, Yutaka ,  YASUMURA, Koichi ,  KODAMA, Takeshi ,  OTSUJI, Shun ,  KAN, Keizo ,  SUMIDA, Takumi

IPC分类号： A61K31/495 ,  A61K31/496 ,  A61P35/00

CPC分类号： A61K31/496 ,  A61K31/495

摘要： An object of the present invention is to provide a medicinal drug much improved in anti tumor activity and excellent in safety. According to the present invention, there is provided a medicinal drug containing a compound represented by the following general formula (1) or a salt thereof as an active ingredient: [Formula 1] wherein X1 represents a nitrogen atom or a group -CH=, R1 represents a group -Z-R6, in which Z represents a group -CO-, a group -CH(OH)- or the like, R6 represents a 5- to 15-membered monocyclic, dicyclic or tricyclic saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms or sulfur atoms, R2 represents a hydrogen atom or a halogen atom, Y represents a group -O-, a group -CO-, a group -CH(OH)- or a lower alkylene group, and A represents [Formula 2] wherein R3 represents a hydrogen atom, a lower alkoxy group or the like, p represents 1 or 2, R4 represents an imidazolyl lower alkyl group or the like.

公开(公告)号：EP1954684A2

公开(公告)日：2008-08-13

申请号：EP06823467.3

申请日：2006-11-14

申请人： Otsuka Pharmaceutical Co., Ltd.

发明人： OKADA, Minoru ,  KATO, Masaya ,  SATO, Norifumi ,  UNO, Tetsuyuki ,  KITAGAKI, Hideki ,  HARUTA, Junpei ,  HIYAMA, Hidetaka ,  SHIBATA, Tomonori

IPC分类号： C07D263/34 ,  C07D263/32 ,  C07D413/12 ,  A61K31/422 ,  A61P17/00

CPC分类号： A61K31/421 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/497 ,  A61K31/5377 ,  C07D263/32 ,  C07D263/34 ,  C07D413/06 ,  C07D413/12 ,  C12N9/16 ,  C12Y301/04012

摘要： The present invention provides a oxazole compound represented by Formula (1), or a salt thereof: wherein R1 is an aryl group which may have one or more substituents; R2 is an aryl group or a nitrogen atom-containing heterocyclic group each of which may have one or more substituents; and W is a divalent group represented by -Y1-A1- or -Y2-C(=O)- wherein Y1 is a group such as -C(=O)-, A1 is a group such as a lower alkylene group, and Y2 is a group such as a piperazinediyl group. The oxazole compound has a specific inhibitory action against phosphodiesterase 4.

公开(公告)号：EP1931425A1

公开(公告)日：2008-06-18

申请号：EP06811551.8

申请日：2006-10-04

申请人： OTSUKA PHARMACEUTICAL CO., LTD.

发明人： MATSUMOTO, Makoto ,  HASHIZUME, Hiroyuki ,  TOMISHIGE, Tatsuo ,  KAWASAKI, Masanori ,  SHIMOKAWA, Yoshihiko

IPC分类号： A61P31/06 ,  A61K31/424 ,  A61K31/454 ,  A61K31/496 ,  A61K45/06

CPC分类号： A61K31/4965 ,  A61K31/133 ,  A61K31/424 ,  A61K31/427 ,  A61K31/451 ,  A61K31/454 ,  A61K31/495 ,  A61K31/496 ,  A61K31/52 ,  A61K31/536 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention provides antituberculous therapeutic drugs with a higher potency. The present invention provides also antituberculous therapeutic drugs containing oxazole compounds represented by (I) general formula (1): [wherein R1 represents a hydrogen atom or C1-6 alkyl group, n represents an integer of 0-6, and R2 represents general formula (A) or the like, wherein R3 represents a phenoxy group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring) or the like], optically active forms thereof or salts thereof, and drugs (II) such as primary antituberculous drugs.

公开(公告)号：EP1927355A1

公开(公告)日：2008-06-04

申请号：EP08000357.7

申请日：2002-09-25

申请人： OTSUKA PHARMACEUTICAL CO., LTD.

发明人： Bando, Takuji ,  Aoki, Satoshi ,  Kawasaki, Junichi ,  Ishigami, Makoto ,  Taniguchi, Youichi ,  Yabuuchi, Tsuyoshi ,  Fujimoto, Kiyoshi ,  Nishioka, Yoshihiro ,  Kobayashi, Noriyuki ,  Fujimura, Tsutomu ,  Takahashi, Masanori ,  Abe, Kaoru ,  Nakagawa, Tomonori ,  Shinhama, Koichi ,  Utsumi, Naoto ,  Tominaga, Michiaki ,  Oi, Yoshihiro ,  Yamada, Shohei ,  Tomikawa, Kenji

IPC分类号： A61K31/496 ,  C07D215/22 ,  A61P25/18

CPC分类号： C07D215/227 ,  C07B2200/13 ,  C07D215/22 ,  Y10T428/2982

摘要： The present invention provides an improved low hygroscopic form, form F, of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the aripiprazole anhydride crystals is stored for an extended period.

摘要翻译： 本发明提供了阿立哌唑的改进的低吸湿形式，形式F，其制备方法即使在含有阿立哌唑酐晶体的药物制剂长时间储存​​时也不会转化为水合物或失去其原始溶解度。

公开(公告)号：EP1906926A1

公开(公告)日：2008-04-09

申请号：EP06781620.7

申请日：2006-07-19

申请人： OTSUKA PHARMACEUTICAL CO., LTD.

发明人： KAWASAKI, Junichi OTSUKA PHARMACEUTICAL CO., LTD.

IPC分类号： A61K9/14 ,  A61K31/454 ,  A61K31/496 ,  A61K31/47

CPC分类号： A61K9/1652 ,  A61K9/1617 ,  A61K31/454 ,  A61K31/47 ,  A61K31/496

摘要： A pharmaceutical composition according to the present invention comprises: (I) at least one member selected from the group consisting of oxazole compounds, optically active isomers thereof, and salts thereof, the oxazole compounds being represented by general formula (1): wherein R1 represents a hydrogen atom or C1-6 alkyl group; n represents an integer from 0 to 6; and R2 represents, for example, a group of general formula (A) shown below: wherein R3 represents a phenoxy group, optionally substituted on the phenyl ring with one or more members selected from the group consisting of halogen atoms, halo-substituted or unsubstituted C1-6 alkyl groups, and halo-substituted or unsubstituted C1-6 alkoxy groups; and (II) at least one cellulose compound selected from the group consisting of hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate. The present pharmaceutical composition has an improved oxazole compound water solubility.

公开(公告)号：EP1656942A3

公开(公告)日：2008-02-27

申请号：EP05025442.4

申请日：1998-08-04

申请人： OTSUKA PHARMACEUTICAL CO., LTD.

发明人： Uchiyama, Shigeto ,  Ueno, Tomomi c/o Saga Laboratories of Otsuka Pharm ,  Imaizumi, Kiyoko c/o Tokushima Labor. of Otsuka Ph ,  Kumemura, Megumi ,  Masaki, Kyosuke ,  Shimizu, Seiichi

IPC分类号： A61K35/74 ,  A61K31/35

CPC分类号： C12R1/46 ,  A23C9/1236 ,  A23C9/1315 ,  A23C11/106 ,  A23L2/52 ,  A23L21/15 ,  A23L29/065 ,  A23L33/105 ,  A23L33/11 ,  A23L33/135 ,  A23L33/185 ,  A61K31/35 ,  A61K35/74 ,  A61K35/744 ,  A61K36/48 ,  C12P17/06 ,  C12R1/01 ,  A61K2300/00

摘要： The present invention relates to a composition comprising a daidzein-containing substance and a strain of microorganism capable of metabolizing daidzein to equol as essential ingredients.